Scott Schobel, MD, MSc, Associate Group Medical Director and Clinical Science Leader for the IONIS/Roche HTT Rx program at Roche/Genentech Neuroscience discusses Huntington’s disease and the GENERATION HD1 trial (Global EvaluatioN of Efficacy and Safety of Roche/Genentech AnTIsense OligoNucletide for Huntington’s Disease).

The GENERATION HD1 study (NCT03761849) is assessing whether RG6042 delays disease progression. RG6042 is the first therapy in development for Huntinton’s disease designed to target the underlying cause of the disease by limiting production and lowering the levels of the specific toxic protein that breaks down the nerve cells in the brain, which may affect an individual’s everyday functions such as mobility and thinking.